These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 26250435

  • 1. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
    [Abstract] [Full Text] [Related]

  • 2. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 3. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 4. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):111-120. PubMed ID: 32049331
    [Abstract] [Full Text] [Related]

  • 6. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
    Kalra PA, Bhandari S, Spyridon M, Davison R, Lawman S, Mikhail A, Reaich D, Pritchard N, McCafferty K, Moore J.
    BMC Nephrol; 2020 Dec 10; 21(1):539. PubMed ID: 33302891
    [Abstract] [Full Text] [Related]

  • 7. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI.
    Transfusion; 2018 Apr 04; 58(4):974-981. PubMed ID: 29424441
    [Abstract] [Full Text] [Related]

  • 14. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
    Jensen G, Gøransson LG, Fernström A, Furuland H, Christensen JH.
    Clin Nephrol; 2019 Apr 04; 91(4):246-253. PubMed ID: 30614439
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
    Johansson PI, Rasmussen AS, Thomsen LL.
    Vox Sang; 2015 Oct 04; 109(3):257-66. PubMed ID: 25900643
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Iron (III) isomaltoside 1000.
    Mace TA, Syed A, Bhandari S.
    Expert Rev Hematol; 2013 Jun 04; 6(3):239-46. PubMed ID: 23782077
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.